Daiwa Securities Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-58
| Closed | -$11K | – | 1327 |
|
|
2025
Q4 | $11K | Sell |
58
-5
| -8% | -$961 | ﹤0.01% | 1180 |
|
|
2025
Q3 | $11K | Hold |
63
| – | – | ﹤0.01% | 1154 |
|
|
2025
Q2 | $7K | Hold |
63
| – | – | ﹤0.01% | 1135 |
|
|
2025
Q1 | $7K | Hold |
63
| – | – | ﹤0.01% | 1112 |
|
|
2024
Q4 | $7K | Hold |
63
| – | – | ﹤0.01% | 1148 |
|
|
2024
Q3 | $6K | Hold |
63
| – | – | ﹤0.01% | 1159 |
|
|
2024
Q2 | $5K | Hold |
63
| – | – | ﹤0.01% | 1199 |
|
|
2024
Q1 | $5K | Hold |
63
| – | – | ﹤0.01% | 1210 |
|
|
2023
Q4 | $4K | Hold |
63
| – | – | ﹤0.01% | 1226 |
|
|
2023
Q3 | $4K | Hold |
63
| – | – | ﹤0.01% | 1175 |
|
|
2023
Q2 | $5K | Hold |
63
| – | – | ﹤0.01% | 1181 |
|
|
2023
Q1 | $5K | Hold |
63
| – | – | ﹤0.01% | 1154 |
|
|
2022
Q4 | $4K | Sell |
63
-38
| -38% | -$2.47K | ﹤0.01% | 1169 |
|
|
2022
Q3 | $5K | Hold |
101
| – | – | ﹤0.01% | 1160 |
|
|
2022
Q2 | $6K | Buy |
101
+22
| +28% | +$1.25K | ﹤0.01% | 1160 |
|
|
2022
Q1 | $6K | Hold |
79
| – | – | ﹤0.01% | 1160 |
|
|
2021
Q4 | $8K | Sell |
79
-12
| -13% | -$1.11K | ﹤0.01% | 1162 |
|
|
2021
Q3 | $8K | Buy |
91
+38
| +72% | +$2.94K | ﹤0.01% | 1155 |
|
|
2021
Q2 | $4K | Hold |
53
| – | – | ﹤0.01% | 1091 |
|
|
2021
Q1 | $5K | Buy |
53
+5
| +10% | +$473 | ﹤0.01% | 1076 |
|
|
2020
Q4 | $3K | Sell |
48
-99
| -67% | -$5.64K | ﹤0.01% | 1089 |
|
|
2020
Q3 | $9K | Hold |
147
| – | – | ﹤0.01% | 1047 |
|
|
2020
Q2 | $7K | Hold |
147
| – | – | ﹤0.01% | 1089 |
|
|
2020
Q1 | $7K | Sell |
147
-12
| -8% | -$680 | ﹤0.01% | 1082 |
|
|
2019
Q4 | $10K | Sell |
159
-38
| -19% | -$2.54K | ﹤0.01% | 1064 |
|
|
2019
Q3 | $12K | Hold |
197
| – | – | ﹤0.01% | 1024 |
|
|
2019
Q2 | $14K | Sell |
197
-11
| -5% | -$810 | ﹤0.01% | 1035 |
|
|
2019
Q1 | $16K | Buy |
208
+20
| +11% | +$1.51K | ﹤0.01% | 1001 |
|
|
2018
Q4 | $16K | Hold |
188
| – | – | ﹤0.01% | 978 |
|
|
2018
Q3 | $32K | Hold |
188
| – | – | ﹤0.01% | 981 |
|
|
2018
Q2 | $24K | Hold |
188
| – | – | ﹤0.01% | 1007 |
|
|
2018
Q1 | $19K | Buy |
+188
| New | +$18.6K | ﹤0.01% | 992 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Daiwa Securities Group's LGND Position: Q1 2026 in Review
Daiwa Securities Group sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 58 shares — an estimated $11K sold.
Daiwa Securities Group first reported a position in LGND in Q1 2018 and held it in 32 quarters. The position peaked at $32K in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Daiwa Securities Group reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 58 Ligand Pharmaceuticals shares in Q1 2026, an estimated $11K.
- Daiwa Securities Group first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 32 quarters.
- Daiwa Securities Group's Ligand Pharmaceuticals position peaked at $32K in Q3 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.